Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions. In August of 2023, Reunion Neuroscience became a private company and in May 2024, the Company completed a Series A financing co-led by MPM BioImpact and Novo Holdings. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression and adjustment disorder, as well as in additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care.
The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe postpartum depression (PPD) patients. Reunion plans to initiate the REKINDLE Phase 2 clinical trial, a randomized, double-blind, parallel-group, dose-controlled trial in adjustment disorder (AjD) in cancer and other medical illnesses.
The RECONNECT Phase 2 clinical trial (NCT06342310), a multicenter, randomized, double-blind, active dose-controlled clinical trial, is evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. To learn more about the study and eligibility for enrollment, please visit www.ppdreconnectstudy.com.
Company Details
- Employees
- 23
- Industry
- Biotechnology
- Website
- https://www.reunionneuro.com
- Keywords
- Westmont.
Reunion Neuroscience Questions
Reunion Neuroscience's website is https://www.reunionneuro.com
Reunion Neuroscience's LinkedIn profile is https://www.linkedin.com/company/reunionneuro
Reunion Neuroscience has
23 employees.
View email and phone details for 23
employees at Reunion Neuroscience.
Reunion Neuroscience's industry is
Biotechnology
Reunion Neuroscience's top competitors are
Cybin Inc,
Seaport Therapeutics,
Field Trip Health (Now Stella Mental Health),
Mindmed,
Beckley Psytech,
Mpm Bioimpact,
Latus Bio,
Lykos Therapeutics,
Atai Life Sciences,
Delphia Therapeutics.
Reunion Neuroscience's categories are Biotechnology
